PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
PLOS BLOGS Speaking of Medicine and Health
Browse all PLOS Blogs
Browse all PLOS Blogs

This Week in PLoS Medicine: Gastroenteritis economics; Prenatal treatment of toxoplasmosis; Genomic medicine & public health

Michael Morris General

Image Credit: Ke Hu and John Murray

Three new articles were published this week in PLoS Medicine:

Stephen Freedman and colleagues performed a cost analysis of the routine administration of ondansetron in both the United States and Canada and show that its routine administration to eligible children in such settings could provide substantial benefit.

An observational study by Ruth Gilbert and colleagues finds that prenatal treatment of congenital toxoplasmosis could substantially reduce the proportion of infected fetuses that develop serious neurological sequelae.

Wayne Hall and colleagues discuss the limitations of genomic risk prediction for population-level preventive health care.

Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Back to top